Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer.
Chakraborty S, Sen U, Ventura K, Jethalia V, Coleman C, Sridhar S, Banerjee A, Ozakinci H, Mahendravarman Y, Snioch K, de Stanchina E, Shields MD, Tomalin LE, Demircioglu D, Boyle TA, Tocheva A, Hasson D, Sen T.
Chakraborty S, et al. Among authors: ozakinci h.
Cell Rep Med. 2025 Jan 18:101944. doi: 10.1016/j.xcrm.2025.101944. Online ahead of print.
Cell Rep Med. 2025.
PMID: 39827880
Free article.
No abstract available.